文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

二价呼吸道合胞病毒预融合F蛋白疫苗预防老年人心血管住院:DAN-RSV试验的预设分析

Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在60岁及以上成人中,接种RSVpreF疫苗使全因心肺住院率显著低于未接种(9.9%),但全因心血管住院无显著差异。

DAN-RSV试验的预设二次分析,在丹麦2024-2025年冬季开展,纳入60岁及以上成人131276例,1:1随机接种RSVpreF疫苗或不接种。从预约访视后14天随访至2025年5月31日,RSVpreF组全因心肺住院发生率为26.3/1000人年,对照组为29.2/1000人年,绝对率降低2.90/1000人年(95%CI 0.10-5.71),疫苗有效性9.9%(95%CI 0.3%-18.7%,P=0.04)。全因心血管住院疫苗有效性7.4%(95%CI -5.5%至18.8%,P=0.24),无统计学显著差异;卒中、心肌梗死、心力衰竭住院和房颤均无显著组间差异。

要点

  • 60岁及以上成人接种RSVpreF疫苗后,全因心肺住院率26.3 vs 29.2事件/1000人年,绝对率降低2.90/1000人年(95%CI 0.10-5.71),疫苗有效性9.9%(95%CI 0.3%-18.7%,P=0.04)。
  • 全因心血管住院率RSVpreF组16.4 vs 对照组17.7事件/1000人年,疫苗有效性7.4%(95%CI -5.5%至18.8%,P=0.24),未达统计学显著。
  • 基线有无心血管疾病对疫苗效果的交互作用无统计学意义(有CVD:5.0%[95%CI -11.2%至16.7%];无CVD:15.2%[95%CI 2.2%-27.1%];交互P=0.27)。
  • 卒中发生率RSVpreF组3.0 vs 对照组3.8事件/1000人年,疫苗有效性19.4%(95%CI -8.6%至40.4%,P=0.14),未达统计学显著。
  • 心肌梗死、心力衰竭住院和房颤的组间差异均无统计学意义。

适用人群与场景

  • 丹麦2024-2025年冬季开展,60岁及以上成人,无论有无合并症均符合纳入条件。
  • 纳入131276例,平均年龄69.4岁(SD 6.5),男性50.3%,基线有心血管疾病者28662例(21.8%)。

处置流程与药物剂量

  • 参与者1:1随机接受RSVpreF疫苗(n=65642)或不接种疫苗(n=65634)。
  • 结局从预约研究访视后14天评估至2025年5月31日。

研究设计与关键结果

  • 预设二次分析,实用型、开放标签、个体随机临床试验,2024-2025年冬季在丹麦开展,首例参与者于2024年11月18日入组。
  • 全因心肺住院:RSVpreF组26.3 vs 对照组29.2事件/1000人年,绝对率降低2.90/1000人年(95%CI 0.10-5.71),疫苗有效性9.9%(95%CI 0.3%-18.7%,P=0.04)。
  • 全因心血管住院:RSVpreF组16.4 vs 对照组17.7事件/1000人年,疫苗有效性7.4%(95%CI -5.5%至18.8%,P=0.24)。
  • 卒中:RSVpreF组3.0 vs 对照组3.8事件/1000人年,疫苗有效性19.4%(95%CI -8.6%至40.4%,P=0.14)。
  • 基线CVD状态交互作用:有CVD者疫苗有效性5.0%(95%CI -11.2%至16.7%),无CVD者15.2%(95%CI 2.2%-27.1%),交互P=0.27。
  • 心肌梗死、心力衰竭住院和房颤的组间差异均无统计学意义。

证据类型、等级与局限

  • 证据类型:实用型、开放标签、个体随机临床试验的预设二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果提示RSV免疫接种可能带来下游心肺获益,尽管对全因心血管住院的影响未达统计学显著。
  • 在60岁及以上成人中,接种RSVpreF疫苗可使全因心肺住院率显著低于不接种。

指南或共识出处

  • DAN-RSV试验(ClinicalTrials.gov标识符NCT06684743)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Respiratory syncytial virus (RSV) infection is linked to elevated cardiovascular risk, particularly in individuals with preexisting cardiovascular disease (CVD). A bivalent RSV prefusion F protein (RSVpreF) vaccine was recently approved for preventing RSV-related lower respiratory tract illness, but its effectiveness against cardiovascular outcomes has not been evaluated in a randomized trial.

OBJECTIVE: To investigate the vaccine effectiveness of RSVpreF compared with no vaccine against cardiovascular outcomes among adults aged 60 years or older.

DESIGN, SETTING, AND PARTICIPANTS: Prespecified secondary analysis of the DAN-RSV trial, a pragmatic, open-label, individually randomized clinical trial conducted in Denmark during the 2024-2025 winter season. The first participant was enrolled on November 18, 2024. Adults aged 60 years or older were eligible for inclusion regardless of comorbidity status.

INTERVENTIONS: Participants were randomized 1:1 to receive RSVpreF (n = 65 642) or no vaccine (n = 65 634).

MAIN OUTCOMES AND MEASURES: Hospitalization for any cardiorespiratory disease was a prespecified secondary outcome, and hospitalizations for any CVD, heart failure, myocardial infarction, stroke, and atrial fibrillation were prespecified exploratory outcomes. Outcomes were assessed from 14 days after booked study visit through May 31, 2025. Vaccine effectiveness was calculated as 1 - incidence rate ratio, expressed as a percentage.

RESULTS: Of 131 276 participants included (mean age, 69.4 [SD, 6.5] years; 50.3% male), 28 662 (21.8%) had preexisting CVD. All-cause cardiorespiratory hospitalization incidence was lower in the RSVpreF group compared with the control group (26.3 vs 29.2 events per 1000 participant-years [PY]; absolute rate reduction, 2.90 [95% CI, 0.10-5.71] per 1000 PY; vaccine effectiveness, 9.9% [95% CI, 0.3%-18.7%]; P = .04). There was no significant interaction by baseline CVD status (CVD at baseline: vaccine effectiveness, 5.0% [95% CI, -11.2% to 16.7%]; no CVD at baseline: vaccine effectiveness, 15.2% [95% CI, 2.2%-27.1%]; P = .27 for interaction). For the RSVpreF group vs control group, respectively, incidence rates of all-cause cardiovascular hospitalization were 16.4 vs 17.7 events per 1000 PY (vaccine effectiveness, 7.4% [95% CI, -5.5% to 18.8%]; P = .24), and incidence rates of stroke were 3.0 vs 3.8 events per 1000 PY (vaccine effectiveness, 19.4% [95% CI, -8.6% to 40.4%]; P = .14). There were also no statistically significant between-group differences for myocardial infarction, heart failure hospitalization, and atrial fibrillation.

CONCLUSIONS AND RELEVANCE: In adults aged 60 years or older, all-cause cardiorespiratory hospitalization was significantly lower with RSVpreF than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06684743.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Lassen MCH, Johansen ND, Christensen SH, et al. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025. PMID: 40884493. doi:10.1001/jama.2025.15405

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。